Immunome (IMNM) AGM 2026 summary
Event summary combining transcript, slides, and related documents.
AGM 2026 summary
25 Jun, 2026Opening remarks and agenda
Meeting called to order at 9:00 A.M. Pacific Time, with board members, executive leadership, and auditors present.
Voting instructions provided, with clarification on proxy and online voting procedures.
Inspector of Elections appointed and record date for voting established as April 16, 2026.
Notice of meeting mailed to all stockholders of record, with 113,249,519 shares outstanding and a quorum confirmed.
Four proposals outlined for consideration: director elections, auditor ratification, executive compensation, and vote frequency.
Board and executive committee updates
Election of three Class III directors for terms expiring at the 2029 annual meeting: James Boylan, Philip Wagenheim, and Sandra Swain.
Shareholder proposals
Advisory vote on executive compensation and on the frequency of such votes included among the proposals.
Latest events from Immunome
- FDA accepted NDA for varegacestat; Q2 net loss $73.1M, cash $520M, pipeline advancing.IMNM
Q2 2026 - Advancing global ADC and targeted therapy pipeline, with pivotal AL102 data expected in 2025.IMNM
Guggenheim Securities Inaugural Healthcare Innovation Conference - Varegacestat nears pivotal data with strong differentiation, while ADC innovation advances.IMNM
Guggenheim Securities 2nd Annual Healthcare Innovation Conference - Varegacestat shows strong efficacy as launch nears; ADC pipeline and cash runway support growth.IMNM
Goldman Sachs 47th Annual Global Healthcare Conference 2026 - Varegacestat met all Phase 3 endpoints in desmoid tumors, with NDA filed and strong pipeline progress.IMNM
Investor presentation - NDA filed for varegacestat after strong Phase 3; Q1 net loss $53.8M, cash $582.7M.IMNM
Q1 2026 - Shareholders to vote on director elections, auditor ratification, and executive pay at the annual meeting.IMNM
Proxy filing - 2025 achievements drove pipeline and share growth; Board recommends all proposals at 2026 meeting.IMNM
Proxy filing - Varegacestat achieved best-in-class efficacy and safety in Phase 3 desmoid tumor trial.IMNM
Study Result